CD8A and nonpapillary renal cell carcinoma: HHLA2, with the ability to hinder the human CD4 T-cells and CD8 T-cells proliferation and cytokine production [36], was regarded as a prognostic biomarker and therapeutic target in ccRCC [37–39].